Cargando…
The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma
Cancer genomics and cancer mutation databases have made an available wealth of information about missense mutations found in cancer patient samples. Contextualizing by means of annotation and predicting the effect of amino acid change help identify which ones are more likely to have a pathogenic imp...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569343/ https://www.ncbi.nlm.nih.gov/pubmed/36243772 http://dx.doi.org/10.1038/s41419-022-05318-2 |
_version_ | 1784809834730749952 |
---|---|
author | Tiberti, Matteo Di Leo, Luca Vistesen, Mette Vixø Kuhre, Rikke Sofie Cecconi, Francesco De Zio, Daniela Papaleo, Elena |
author_facet | Tiberti, Matteo Di Leo, Luca Vistesen, Mette Vixø Kuhre, Rikke Sofie Cecconi, Francesco De Zio, Daniela Papaleo, Elena |
author_sort | Tiberti, Matteo |
collection | PubMed |
description | Cancer genomics and cancer mutation databases have made an available wealth of information about missense mutations found in cancer patient samples. Contextualizing by means of annotation and predicting the effect of amino acid change help identify which ones are more likely to have a pathogenic impact. Those can be validated by means of experimental approaches that assess the impact of protein mutations on the cellular functions or their tumorigenic potential. Here, we propose the integrative bioinformatic approach Cancermuts, implemented as a Python package. Cancermuts is able to gather known missense cancer mutations from databases such as cBioPortal and COSMIC, and annotate them with the pathogenicity score REVEL as well as information on their source. It is also able to add annotations about the protein context these mutations are found in, such as post-translational modification sites, structured/unstructured regions, presence of short linear motifs, and more. We applied Cancermuts to the intrinsically disordered protein AMBRA1, a key regulator of many cellular processes frequently deregulated in cancer. By these means, we classified mutations of AMBRA1 in melanoma, where AMBRA1 is highly mutated and displays a tumor-suppressive role. Next, based on REVEL score, position along the sequence, and their local context, we applied cellular and molecular approaches to validate the predicted pathogenicity of a subset of mutations in an in vitro melanoma model. By doing so, we have identified two AMBRA1 mutations which show enhanced tumorigenic potential and are worth further investigation, highlighting the usefulness of the tool. Cancermuts can be used on any protein targets starting from minimal information, and it is available at https://www.github.com/ELELAB/cancermuts as free software. |
format | Online Article Text |
id | pubmed-9569343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-95693432022-10-17 The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma Tiberti, Matteo Di Leo, Luca Vistesen, Mette Vixø Kuhre, Rikke Sofie Cecconi, Francesco De Zio, Daniela Papaleo, Elena Cell Death Dis Article Cancer genomics and cancer mutation databases have made an available wealth of information about missense mutations found in cancer patient samples. Contextualizing by means of annotation and predicting the effect of amino acid change help identify which ones are more likely to have a pathogenic impact. Those can be validated by means of experimental approaches that assess the impact of protein mutations on the cellular functions or their tumorigenic potential. Here, we propose the integrative bioinformatic approach Cancermuts, implemented as a Python package. Cancermuts is able to gather known missense cancer mutations from databases such as cBioPortal and COSMIC, and annotate them with the pathogenicity score REVEL as well as information on their source. It is also able to add annotations about the protein context these mutations are found in, such as post-translational modification sites, structured/unstructured regions, presence of short linear motifs, and more. We applied Cancermuts to the intrinsically disordered protein AMBRA1, a key regulator of many cellular processes frequently deregulated in cancer. By these means, we classified mutations of AMBRA1 in melanoma, where AMBRA1 is highly mutated and displays a tumor-suppressive role. Next, based on REVEL score, position along the sequence, and their local context, we applied cellular and molecular approaches to validate the predicted pathogenicity of a subset of mutations in an in vitro melanoma model. By doing so, we have identified two AMBRA1 mutations which show enhanced tumorigenic potential and are worth further investigation, highlighting the usefulness of the tool. Cancermuts can be used on any protein targets starting from minimal information, and it is available at https://www.github.com/ELELAB/cancermuts as free software. Nature Publishing Group UK 2022-10-15 /pmc/articles/PMC9569343/ /pubmed/36243772 http://dx.doi.org/10.1038/s41419-022-05318-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Tiberti, Matteo Di Leo, Luca Vistesen, Mette Vixø Kuhre, Rikke Sofie Cecconi, Francesco De Zio, Daniela Papaleo, Elena The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma |
title | The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma |
title_full | The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma |
title_fullStr | The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma |
title_full_unstemmed | The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma |
title_short | The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma |
title_sort | cancermuts software package for the prioritization of missense cancer variants: a case study of ambra1 in melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569343/ https://www.ncbi.nlm.nih.gov/pubmed/36243772 http://dx.doi.org/10.1038/s41419-022-05318-2 |
work_keys_str_mv | AT tibertimatteo thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT dileoluca thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT vistesenmettevixø thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT kuhrerikkesofie thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT cecconifrancesco thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT deziodaniela thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT papaleoelena thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT tibertimatteo cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT dileoluca cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT vistesenmettevixø cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT kuhrerikkesofie cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT cecconifrancesco cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT deziodaniela cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma AT papaleoelena cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma |